Objective: This study was undertaken to examine the Kurozu concentrate (KC) based dietary supplement on several obesity-related parameters in obese Japanese male and female adults.Background: Kurozu, which is a specific type of rice vinegar produced by fermentation of unpolished brown rice, has long been used as a traditional health food and folk medicine in Japan. A recent animal study and our preliminary human study suggest that the KC supplement has potential for use in the management of obesity.Materials and Methods: A 12-week, randomized, double-blind, placebo-controlled trial was conducted involving 48 Japanese adult subjects (28 males and 20 females) with obesity. Subjects were either assigned to the group consuming the KC supplement for 12 weeks (870mg/day; 480 mg/day as KC) (n=24; 14 males and 10 females) or the placebo group (n=24; 14 males and 10 females). All test participants were assessed using several obesity-related parameters, including body weight, BMI, waist circumference, and abdominal fat computed tomography (CT) sections. These measurements took place at baseline and at week 12. Results: At week 12, a significant decrease in body weight (P<0.043) and nearly significant decreased values of BMI (P=0.052) were observed in the KC group compared to the placebo group. The reduction in waist circumference at week 12 within the KC group was not significantly greater than the placebo group. Examination of abdominal CT sections around the navel indicated that, although most of the values of the total fat area, subcutaneous fat area, and visceral fat area for both of the placebo and KC groups significantly increased during the 12-week intervention, the magnitude of increase in the total fat area for all subjects and that of the total fat area, subcutaneous fat area, and visceral fat area for females on one or more of three CT sections were significantly lower in the KC group than the placebo group (P<0.05).Conclusion: Although the results are not definitive, KC supplementation may have potential for improving some obesity-related parameters in obese subjects, particularly females.Key words: Kurozu concentrate (KC), KC-based dietary supplement (KC supplement), abdominal obesity-related parameters, body mass index (BMI), computed tomography (CT), abdominal fat
We have investigated the effect
Background: Extracorporeal cardiopulmonary resuscitation (E-CPR) using venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a novel lifesaving method for refractory cardiac arrest (CA). However, VA-ECMO increases damaged left ventricular (LV) afterload. The percutaneous microaxial pump, Impella, can reduce LV preload with simultaneous circulatory support, which may have significant effect on clinical outcome by concomitant use of VA-ECMO and IMPELLA (ECPELLA). In the current retrospective cohort study, we assessed factors affecting outcome of CA patients who underwent E-CPR.Method: We retrospectively reviewed 149 consecutive CA patients with E-CPR from January 2012 through December 2020 in our institute. Patients were divided into three groups, ECEPLLA (n=29), IABP + VA-ECMO (n=78), and single VA-ECMO (n=42). We assessed 30-day survival and neurological outcome using the Cerebral Performance Categories (CPC). Results: There were no significant differences in age, gender, out of hospital CA, acute coronary syndrome among groups. The ECPELLA showed the highest cumulative 30-day survival (ECPELLA: 55%, IABP + VA-ECMO: 23%, VA-ECMO: 9.5; p=0.001) and the rates of CPC score 1 or 2 (ECPELLA: 31%, IABP + VA-ECMO: 13%, VA-ECMO: 7%; p=0.02). Multivariate analysis revealed that age (hazard ratio [HR], 1.30, 95% confidence interval [CI], 1.13-1.52, P=0.005) and Time from CA to ECMO support (HR, 1.22, 95%CI, 1.13-1.31, P<0.0001) and ECPELLA (HR, 0.46, 95%CI, 0.24-0.88, P=0.02) were significantly associated with the clinical outcome. Conclusion: Earlier initiation of E-CPR is critical to improve patient survival and neurological outcome. Additional Impella support, ECPELLA, appears to significantly improve the clinical outcome.
Background: Extracorporeal cardiopulmonary resuscitation (E-CPR) using venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a novel lifesaving method for refractory cardiac arrest (CA). However, VA-ECMO increases damaged left ventricular (LV) afterload. The percutaneous microaxial pump Impella can reduce LV preload with simultaneous circulatory support, which may have a significant effect on clinical outcome by concomitant use of VA-ECMO and IMPELLA (ECPELLA). In the current retrospective cohort study, we assessed factors affecting the outcome of CA patients who underwent E-CPR.Method: We retrospectively reviewed 149 consecutive CA patients with E-CPR from January 2012 through December 2020 in our institute. Patients were divided into three groups: ECEPLLA (n=29), IABP + VA-ECMO (n=78), and single VA-ECMO (n=42). We assessed 30-day survival and neurological outcome using cerebral performance categories (CPCs).Results: There were no significant differences in age, sex, out-of-hospital CA, or acute coronary syndrome among the groups. ECPELLA showed the highest cumulative 30-day survival (ECPELLA: 55%, IABP + VA-ECMO: 23%, VA-ECMO: 9.5; p=0.001) and the rates of CPC score 1 or 2 (ECPELLA: 31%, IABP + VA-ECMO: 13%, VA-ECMO: 7%; p=0.02). Multivariate analysis revealed that age (hazard ratio [HR], 1.30, 95% confidence interval [CI], 1.13-1.52, P=0.005) and time from CA to ECMO support (HR, 1.22, 95% CI, 1.13-1.31, P<0.0001) and ECPELLA (HR, 0.46, 95% CI, 0.24-0.88, P=0.02) were significantly associated with the clinical outcome.Conclusion: Earlier initiation of E-CPR is critical to improve patient survival and neurological outcome. Additional Impella support, ECPELLA, appears to significantly improve the clinical outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.